{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-065728","form_type":"8-K","ticker":"RNAZ","cik":"0001829635","company_name":"Transcode Therapeutics, Inc.","filed_at":"2026-05-22T20:15:37+00:00","discovered_at":"2026-05-22T20:17:00.302363+00:00","generated_at":"2026-05-22T20:18:14.789344+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"confidence":"high","headline":"TransCode Therapeutics receives Nasdaq deficiency notice for low stockholders' equity of $1.25M vs $2.5M minimum","bullets":["Stockholders' equity as of March 31, 2026 was $1,251,427, below Nasdaq's $2,500,000 minimum requirement.","Company has 45 days (until July 3, 2026) to submit a compliance plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180-day extension to regain compliance.","Failure to regain compliance could lead to delisting of common stock (RNAZ) from Nasdaq Capital Market."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-065728","json":"https://secwatch.observer/filing/0001104659-26-065728.json","markdown":"https://secwatch.observer/filing/0001104659-26-065728.md","text":"https://secwatch.observer/filing/0001104659-26-065728.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926065728/0001104659-26-065728-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926065728/tm2615385d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T20:18:14.789344+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9687284dc7e3a19aeab306227984f7b56ae2488a","claim":"Transcode Therapeutics, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"On May 19, 2026, TransCode Therapeutics, Inc. (the “Company”) received a deficiency letter from the Listing Qualifications Department (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying the Company that it is not in compliance with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market.","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1829635/000110465926065728/0001104659-26-065728-index.htm","confidence":0.95}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}